David Bredt sold $247k of RAPP
Chief Scientific Officer at Rapport Therapeutics, Inc.. 8,500 shares at an average of $29.02, traded Feb 17, 2026, filed Feb 19, 2026.
Score components
- +15RoleOfficer
- +13Trade size$247k at market
- 0Share of holdings soldSold 2.1% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-059883, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -900 | $28.02 | $25k | 394,675 | Feb 19, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -5,400 | $28.95 | $156k | 389,275 | Feb 19, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -2,200 | $29.59 | $65k | 387,075 | Feb 19, 2026 |
| Feb 19, 2026 | MOption exercise Common Stock10b5-1 | +6,000 | $1.80 | $11k | 393,075 | Feb 19, 2026 |
| Feb 19, 2026 | MOption exercise Stock Options (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 88,080 | Feb 19, 2026 |
Related signals
Other insiders at Rapport Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $143k 4,522 shares | -1% | |
| 23Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $332k 10,000 shares | -7% | |
| 22Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $87k 2,210 shares | -0% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $374k 8,210 shares | -2% | |
| 22Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $282k 10,000 shares | -6% | |
| 17Weak | Rapport Therapeutics, Inc. | Krishnaswamy Yeleswaram Chief Development Officer | $303k 10,115 shares | -3% | |
| 27Weak | RAPPsell Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $58k 2,014 shares | -1% | |
| 27Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $320k 10,916 shares | -2% | |
| 27Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $285k 10,916 shares | -2% | |
| 16Weak | Rapport Therapeutics, Inc. | David Bredt Chief Scientific Officer | $228k 8,500 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.